Tofersen and the mixed results of treatment for the deadly neurodegenerative disease.
Biogen
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory
Enjaymo: First Drug to Treat Cold Agglutinin Disease
Sutimlimab will reduce the need for red blood cell transfusion due to hemolysis.
Posted inClinical Trials, In the Pipeline, Neuroscience
Treating Parkinson’s Disease: Betting on Alpha-Synuclein
The pharmaceutical industry continues to fight hard against the devastating neurodegenerative disease.
Posted inClinical Trials, Neuroscience
Buntanetap: Breakthrough in Treatment of Alzheimer’s and Parkinson’s
Buntanetap acts simultaneously on three neurotoxic proteins responsible for neurodegenerative disorders: amyloid beta, alpha-synuclein, and tau protein.
Posted inNeuroscience, Pharma & Biotech, Rare/Orphan Diseases
Biogen to Develop Updated Version of Spinraza
Nusinersen for the treatment of spinal muscular atrophy will get a follow-up.
Posted inMergers & Acquisitions, Neuroscience
Samsung Wants to Buy Biogen
The price tag is over $42 billion.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
